BBNX Beta Bionics, Inc.
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1674632 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY43.7%
TTM net income YoY-6.8%
TTM EPS YoY57.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin58.6%
Operating margin-72.7%
Net margin-65.3%
FCF margin-51.8%
EBITDA margin-70.6%
Returns
ROE-23.9%
ROA-21.5%
ROIC (approx.)-25.4%
Asset turnover0.33x
Leverage & solvency
Liabilities / assets9.5%
Debt / equity0.00x
Current ratio8.92x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.71x
Accruals ratio-6.1%
Payout ratio—
Capex / revenue5.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $100.25M | $65.12M |
| Cost of revenue | $44.71M | $29.24M |
| Gross profit | $55.54M | $35.89M |
| R&D expense | $34.79M | $26.18M |
| SG&A expense | $31.02M | $17.87M |
| Operating income | -$71.68M | -$45.25M |
| Income tax | $0 | $0 |
| Net income | -$73.20M | -$54.76M |
| EBITDA | -$70.11M | -$44.10M |
| EPS (basic) | -1.81 | -8.60 |
| EPS (diluted) | -1.81 | -8.60 |
| Weighted avg. shares (diluted) | 40.53M | 6.37M |
| Balance sheet | ||
| Cash & equivalents | $31.58M | $30.53M |
| Short-term investments | $187.55M | $73.14M |
| Receivables | $17.12M | $12.00M |
| Inventory | $21.72M | $13.32M |
| Current assets | $267.90M | $132.92M |
| PP&E, net | $8.60M | $4.78M |
| Total assets | $328.74M | $149.65M |
| Current liabilities | $30.92M | $21.15M |
| Total liabilities | $41.13M | $73.63M |
| Shareholders' equity | $287.61M | -$245.36M |
| Shares outstanding | 44.36M | 6.67M |
| Cash flow statement | ||
| Operating cash flow | -$50.92M | -$48.27M |
| Capital expenditure | $5.30M | $3.40M |
| Free cash flow | -$56.22M | -$51.67M |
| Investing cash flow | -$162.81M | -$3.48M |
| Financing cash flow | $214.87M | $55.62M |
| Depreciation & amortization | $1.57M | $1.15M |
| Stock-based compensation | $16.38M | $6.38M |
Free plan shows the latest 2 periods; Pro shows all 3 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.